证券代码：688310 证券简称：迈得医疗 公告编号：2026-014 迈得医疗工业设备股份有限公司 关于股份回购进展公告 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司回购股份进展情况公告如下： 2026 年 3 月，本次公司通过集中竞价交易方式已累计回购公司股份 303,030 股，占公司总股本 166,219,690 股的比例为 0.1823%，回购成交的最高价为 16.50 元/股，最低价为 16.28 元/股，支付的资金总额为人民币 4,979,684.17 元（不含印 花税、交易佣金等交易费用）。 截至 2026 年 3 月 31 日，本次公司通过集中竞价交易方式已累计回购公司股 份 1,600,082 股，占公司总股本 166,219,690 股的比例为 0.9626%，回购成交的最高 价为 16.50 元/股，最低价为 15.69 元/股，支付的资金总额为人民币 25,639,888.96 元（不含印花税、交易佣金等交易费用）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2026-013 迈得医疗工业设备股份有限公司 关于自愿披露控股子公司取得国内医疗器械注册证 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要风险提示： 目前，迈得医疗工业设备股份有限公司（以下简称"公司"）控股子公司 浙江迈得顺隐形眼镜有限公司（以下简称"迈得顺"）隐形眼镜业务属于公司新业 务，尚处于商业化前期，2025 年 1-9 月迈得顺含旗下子公司营业收入仅 5.91 万 元，对公司业绩尚未产生重大影响，其未来生产经营情况尚不明确，受未来经营 管理过程中可能面临宏观经济及行业政策变化、市场竞争等不确定因素的影响， 存在业务拓展不及预期的风险，对公司未来业绩的影响具有不确定性。敬请广大 投资者理性投资，并注意投资风险。 公司控股子公司迈得顺主要从事隐形眼镜研发、生产、销售，于近日取得经 国家药品监督管理局审批的《中华人民共和国医疗器械注册证》，相关情况如下： | 注册人名称 | 浙江迈得顺隐形眼镜有限公司 | | --- | --- | | 产品名称 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2026-012 迈得医疗工业设备股份有限公司 关于2026年度日常关联交易预计的公告 日常关联交易对上市公司的影响：本次关联交易属于迈得医疗工业设备 股份有限公司（以下简称"公司"）日常关联交易，交易符合公开、公平、公正的 原则，不存在损害公司及全体股东特别是中小股东利益的情形，不会影响公司的 独立性，也不会因此类关联交易而对关联方形成重大依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2026 年 3 月 12 日召开第五届董事会第十次会议审议通过了《关于 2026 年度日常关联交易预计的议案》。全体董事一致同意该议案。 公司第五届董事会独立董事专门会议审议通过了《关于 2026 年度日常关联 交易预计的议案》，全体独立董事认为：公司预计 2026 年发生的日常关联交易为 公司日常经营所需，将遵循公平、公正的原则，关联交易定价公允合理，符合有 关法律、法规、规范性文件和《公司章程》等相关规定，不影响公司独立性，不 会对公司财务和经营状况产生不利影响，不存在损害公司及全体股东特别是中小 股东利益的情形。我们一致同意该议案，并同 ...

证券代码：688310 证券简称：迈得医疗 公告编号：2026-011 迈得医疗工业设备股份有限公司 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司回购股份进展情况公告如下： 2026 年 2 月，公司未通过集中竞价交易方式回购公司股份。 截至 2026 年 2 月 28 日，本次公司通过集中竞价交易方式已累计回购公司股 份 1,297,052 股，占公司总股本 166,219,690 股的比例为 0.7803%，回购成交的最高 价为 16.20 元/股，最低价为 15.69 元/股，支付的资金总额为人民币 20,660,204.79 元（不含印花税、交易佣金等交易费用）。 本次回购股份符合法律法规的规定及公司回购股份方案。 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/12/13 | | | | | | | | --- | --- | --- | --- | -- ...

Core Viewpoint - The company reported significant growth in its financial performance for the year 2025, with a notable increase in revenue and net profit, indicating a successful execution of its production plans and market strategies [3][4][5]. Financial Data and Indicators - The company achieved an operating income of 447.42 million yuan, a 62.79% increase compared to the previous year [3][5]. - Operating profit reached 59.70 million yuan, with a total profit of 61.22 million yuan [3]. - The net profit attributable to the parent company was 65.26 million yuan, while the net profit after deducting non-recurring gains and losses was 53.29 million yuan, marking a significant turnaround from losses in the previous year [3][5]. - Total assets at the end of the reporting period were 1.19 billion yuan, up 12.69% year-on-year [3]. - Shareholders' equity attributable to the parent company was 862.40 million yuan, an increase of 6.46% compared to the previous year [3]. - The net asset value per share was 5.19 yuan, reflecting a 6.57% increase year-on-year [3]. Business Performance and Financial Condition - The substantial growth in operating income was attributed to the orderly implementation of production plans, ensuring effective product delivery, and a dual focus on technological innovation and process iteration [4][5]. - The blood purification and medical device combination intelligent equipment sectors performed well, particularly due to strong demand for medical consumables in the terminal market, leading to optimistic market prospects for the medical device combination intelligent equipment [4][5]. - The company emphasized new product development and market expansion around the medical device combination intelligent equipment, resulting in significant revenue growth in this area [4][5].

Core Viewpoint - Maide Medical (688310) reported significant revenue growth for the fiscal year 2025, driven by increased sales in smart medical equipment, marking a successful turnaround to profitability [1] Financial Performance - The company achieved total operating revenue of 447.42 million yuan, representing a year-on-year increase of 62.79% [1] - Operating profit reached 59.70 million yuan, with total profit at 61.22 million yuan, and net profit attributable to shareholders was 65.26 million yuan, indicating a return to profitability [1] - The net profit after deducting non-recurring gains and losses was 53.29 million yuan [1] - Total assets amounted to 1.19 billion yuan, reflecting a year-on-year growth of 12.69% [1] - Shareholders' equity attributable to the parent company was 862.40 million yuan, up 6.46% year-on-year [1] Market Performance - As of February 26, 2026, Maide Medical's stock closed at 17.70 yuan, down 0.73% from the previous trading day [1] - The stock opened at 17.83 yuan, reached a high of 17.94 yuan, and a low of 17.61 yuan, with a trading volume of 37.23 million yuan and a turnover rate of 1.26% [1]

Group 1 - The core viewpoint of the article is that Maide Medical announced a significant increase in revenue and a return to profitability for the year 2025 [2] - The company achieved an operating income of 447.42 million yuan, representing a year-on-year increase of 62.79% [2] - The net profit attributable to the parent company was 65.26 million yuan, marking a turnaround from previous losses [2]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Maide Medical (688310), indicating a slight decline in stock price and mixed financial results for the third quarter of 2025 [1][2]. Group 2 - As of February 26, 2026, Maide Medical's stock closed at 17.7 yuan, down 0.73%, with a turnover rate of 1.26% and a trading volume of 21,000 hands, resulting in a transaction amount of 37.23 million yuan [1]. - The net inflow of main funds on February 26 was 2.239 million yuan, accounting for 6.01% of the total transaction amount, while retail investors experienced a net outflow of 270,200 yuan, representing 0.73% of the total [1]. Group 3 - For the first three quarters of 2025, Maide Medical reported a main revenue of 225 million yuan, a year-on-year increase of 2.31%, and a net profit attributable to shareholders of 8.8367 million yuan, up 15.82% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 83.643 million yuan, reflecting a significant year-on-year increase of 54.38%, and a net profit of 2.7916 million yuan, which is a remarkable increase of 224.07% year-on-year [2]. - The company's debt ratio stands at 29.86%, with an investment income of 167,600 yuan and financial expenses of -523,600 yuan, while the gross profit margin is reported at 40.19% [2]. Group 4 - Maide Medical specializes in the research, production, sales, and service of medical consumables and intelligent equipment, effectively integrating technology in medical device processes, automation, and software to create unique product and service advantages [2].

Group 1 - Hehe Information achieved operating revenue of 1.81 billion yuan in 2025, a year-on-year increase of 25.83%, and net profit of 454 million yuan, a year-on-year increase of 13.39% [1] - Shengyi Technology announced that Guangxin Group and Chen Renxi have completed their share reduction plan, with Guangxin Group reducing its shares by 24.29 million, accounting for 1% of the total share capital [2] - Huaci Co., Ltd. received approval from the China Securities Regulatory Commission for its stock issuance to specific targets [3] Group 2 - New Nuo Wei plans to transfer 30.07% of its shares in Guoxin Huijin to Shiyao Holdings for 230 million yuan, with a valuation increase of 94.85% [4] - Tianli Lithium Energy has completed the scheduled maintenance of its lithium iron phosphate production line and resumed production [5] - Jinchuan Electric reported a net profit of 81.218 million yuan in 2025, a year-on-year decrease of 10.87% [6] Group 3 - Shenzhou Taiyue reported a net profit of 798 million yuan in 2025, a year-on-year decrease of 44.09% [7] - Jingwei Hengrun achieved a net profit of 99.5375 million yuan in 2025, reversing a loss from the previous year [8] - Keheng Technology signed a maximum pledge contract worth 450 million yuan to support its supply chain procurement [9] Group 4 - Zhongchu Media reported a net loss of 20.2858 million yuan in 2025, with operating revenue of 157 million yuan, a year-on-year decrease of 18.99% [10] - Tongde Chemical's subsidiary is involved in a lawsuit with a claim amount of approximately 49.1824 million yuan [12] - Jichuan Pharmaceutical signed an exclusive commercialization rights agreement for a new eczema treatment, with payments not exceeding 190 million yuan [13] Group 5 - Tianli Lithium Energy reported a net loss of 211 million yuan in 2025, with operating revenue of 408 million yuan, a year-on-year decrease of 20.20% [14] - Fortune Trend achieved a net profit of 315 million yuan in 2025, a year-on-year increase of 3.62% [15] - CITIC Securities received approval to publicly issue corporate bonds totaling no more than 80 billion yuan [16] Group 6 - Yongshan Lithium Industry reported a reduction of 23 million shares by Ningbo Jutai, decreasing its total shareholding from 13.24% to 4.52% [17] - Taifu Pump Industry achieved a net profit of 17.5631 million yuan in 2025, a year-on-year increase of 38.78% [18] - Longxun Co., Ltd. reported a net profit of 172 million yuan in 2025, a year-on-year increase of 19.05% [19] Group 7 - Duori Pharmaceutical's acquisition offer period has expired, and the company's stock will resume trading [20] - Tianhao Energy obtained a loan commitment letter for stock repurchase from a financial institution, with a loan amount not exceeding 90 million yuan [21] - Lijun Co., Ltd. reported a net profit of 57.545 million yuan in 2025, a year-on-year decrease of 52.09% [22] Group 8 - Zhongchumai reported a net profit of 212 million yuan in 2025, a year-on-year increase of 45.55% [23] - Kangxino reported a net profit of 27.8727 million yuan in 2025, reversing a loss from the previous year [24] - Baiao Saitu achieved a net profit of 173 million yuan in 2025, a year-on-year increase of 416.37% [25] Group 9 - Guangxun Technology's private placement application was approved by the Shenzhen Stock Exchange [26] - Sandam Membrane reported a net profit of 378 million yuan in 2025, a year-on-year increase of 19.95% [27] - Shangsheng Electronics reported a net profit of 184 million yuan in 2025, a year-on-year decrease of 21.71% [28] Group 10 - Xin'an Century reported a net profit of 79.2904 million yuan in 2025, reversing a loss from the previous year [29] - Zhenlei Technology achieved a net profit of 133 million yuan in 2025, a year-on-year increase of 582.01% [30] - Fuan Pharmaceutical's subsidiary received approval for a new drug application [32] Group 11 - Baotai reported a net loss of 336 million yuan in 2025, with operating revenue of 934 million yuan [33] - Aohua Endoscope reported a net profit of 11.4619 million yuan in 2025, a year-on-year decrease of 45.45% [34] - Maide Medical reported a net profit of 65.2599 million yuan in 2025, reversing a loss from the previous year [35] Group 12 - Chip Original Co. reported a net loss of 528 million yuan in 2025, with operating revenue of 3.152 billion yuan [36] - Zhongwei Semiconductor set a preliminary transfer price of 43.35 yuan per share for its inquiry [37] - Tieke Railway reported a net profit of 171 million yuan in 2025, a year-on-year decrease of 20.09% [38] Group 13 - Changjiang Electric announced a cash dividend distribution plan of 2.1 yuan per 10 shares for the 2025 fiscal year [39] - Kunheng Shunwei reported a net profit of 46.7676 million yuan in 2025, a year-on-year increase of 26.28% [40] - Ailis reported a net profit of 2.181 billion yuan in 2025, a year-on-year increase of 52.55% [41] Group 14 - Aerospace Software reported a net loss of 11.3126 million yuan in 2025, with operating revenue of 1.216 billion yuan [42] - Qizhong Technology reported a net profit of 266 million yuan in 2025, a year-on-year decrease of 15.16% [43] - Guotou Zhonglu plans to acquire 70% of Luochuan Lingxian Company for 74.8745 million yuan [44] Group 15 - Aokema plans to acquire 45% of its subsidiary for 253 million yuan [45] - ST Dali signed a procurement framework agreement worth 88.8794 million yuan with a leading new energy company [46] - Zhifei Biological received clinical trial approval for a new mRNA vaccine [47]

Core Viewpoint - The company, Maide Medical, is set to release its 2025 annual report, showing significant growth in net profit and revenue, indicating a strong operational performance and market demand for its products [1][2]. Financial Performance - In 2025, the company achieved an operating income of 447.42 million yuan, a year-on-year increase of 62.79% [2]. - The operating profit reached 59.70 million yuan, with a total profit of 61.22 million yuan, and a net profit attributable to the parent company of 65.26 million yuan, marking a substantial turnaround from losses [2][3]. - The net profit after deducting non-recurring gains and losses was 53.29 million yuan, reflecting significant improvement compared to the previous year [2]. Asset and Equity Growth - As of the end of the reporting period, total assets amounted to 1.19 billion yuan, up 12.69% from the previous year [2]. - The equity attributable to the parent company was 862.40 million yuan, an increase of 6.46% year-on-year [2]. - The net asset per share attributable to the parent company was 5.19 yuan, reflecting a 6.57% increase compared to the previous year [2]. Business Drivers - The substantial growth in operating income is attributed to the effective implementation of production plans, ensuring timely product delivery, and a dual focus on technological innovation and process iteration [2][3]. - The blood purification and medical device combination intelligent equipment sectors performed well, particularly due to strong market demand for medical consumables [2]. - The company is optimistic about the market demand for medical device combinations and is focusing on new product development and market expansion in this area [2].